Related Experiment Video
Updated: Jul 25, 2025
05:51
Characterization of a Novel Human Organotypic Retinal Culture Technique
Published on: June 9, 2021
4.0K
Interleukin-6 in retinal diseases: From pathogenesis to therapy
Ruihan Xiao1, Chunyan Lei1, Yi Zhang1
1Department of Ophthalmology and Research Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu, 610041, China.
Experimental Eye Research
|June 29, 2023
Summary
Interleukin-6 (IL-6) is a key cytokine in inflammation and cell processes. Targeting IL-6 shows promise for treating various retinal diseases by modulating its role in pathogenesis.
Area of Science:
- Ophthalmology
- Immunology
- Molecular Biology
Background:
- Interleukin-6 (IL-6) is a pleiotropic cytokine involved in immunomodulation, inflammation, and cell proliferation.
- IL-6 exerts its biological effects through classic and trans-signaling pathways.
- IL-6 is implicated in the pathogenesis of numerous retinal diseases.
Purpose of the Study:
- To comprehensively review the biological functions of IL-6.
- To elucidate the mechanisms of IL-6 in the pathogenesis of various retinal diseases.
- To summarize current and prospective therapeutic strategies targeting IL-6 and its receptor for retinal diseases.
Main Methods:
- Literature review of studies on IL-6 biology and retinal diseases.
- Analysis of IL-6 signaling pathways in ocular inflammation.
- Survey of drugs targeting IL-6 and its receptor.
Main Results:
- IL-6 plays a critical role in the development of diabetic retinopathy, uveitis, age-related macular degeneration, glaucoma, retinal vein occlusion, central serous chorioretinopathy, and proliferative vitreoretinopathy.
- IL-6 signaling is a significant factor in the progression of these retinal conditions.
- Several drugs targeting IL-6 and its receptor are under development or in use.
Conclusions:
- IL-6 is a crucial mediator in the pathogenesis of diverse retinal diseases.
- Targeting IL-6 and its receptor represents a promising therapeutic avenue for managing retinal diseases.
- Further research into IL-6 targeted therapies may offer novel treatment strategies for ocular conditions.
